[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitätsklinikum Hamburg-Eppendorf\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":695},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,50,88,115,136,163,191,214,246,273,296,327,354,378,405,432,455,488,519,539,566,588,617,649,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639882","creating-encounters-between-generations---together-instead-of-alone-gemse-100639882",false,"NCT07581171","Creating Encounters Between Generations - Together Instead of Alone (GemsE)","Creating Encounters: Generations in Action - Together Instead of Alone (GemsE)","GemsE","Inclusion Criteria:\n\n* Older adults aged 60 years and older who are residents of Hamburg\n* Children and adolescents aged 12 to 21 years with at least one parent with a mental illness and who are residents of Hamburg\n* Sufficient German language proficiency\n* Ability and willingness to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Children and adolescents with severe acute psychological symptoms requiring inpatient treatment, including acute suicidality, acute substance use, or acute psychotic symptoms\n* Older adults with acute psychological crises or untreated severe mental illness preventing reliable participation\n* Older adults with cognitive impairment or dementia preventing reliable participation in the intervention","ALL","12 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Elderly people and children and young people (CYP) and from families with mentally ill parents are particularly affected by loneliness. The GemsE project is investigating whether intergenerational mentoring between seniors and children or young people helps to reduce loneliness and improve the mental well-being and quality of life of both groups. The aim of the study is to scientifically record the effect of these sponsorships and to find out how such encounters can be successfully organized.",[28,29,30],"Loneliness","Mental Well-being","Health-related Quality of Life",[32,33,34,35,36],"elderly people","children of parents with mental illness","loneliness","psychosocial health","intergenerational tandems","RECRUITING","2026-08-05",{"date":40,"type":41},"2026-08-10","ACTUAL",{"date":43,"type":22},"2026-09-01",{"date":45,"type":22},"2026-12-01",{"name":47,"class":48},"Universitätsklinikum Hamburg-Eppendorf","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100647047","d-tect-pretreatment-d-dimers-and-disease-control-in-advanced-cscc-treated-with-cemiplimab-100647047","NCT07684066","D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab","D-TECT: Prospective Multicenter Evaluation of Pretreatment D-dimer Levels as a Predictor of Disease Control in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab","D-TECT","Inclusion Criteria:\n\n* Histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma\n* Planned initiation of systemic treatment with cemiplimab as part of routine clinical care\n* Pretreatment D-dimer measurement performed within 7 days before initiation of cemiplimab treatment up to the day of first administration before infusion\n* Age 18 years or older at the time of consent\n* ECOG performance status 0 to 2\n* Written informed consent for study participation and pseudonymized collection and analysis of clinical and laboratory data\n\nExclusion Criteria:\n\n* Prior treatment with immune checkpoint inhibitors in curative or palliative intent for cutaneous squamous cell carcinoma\n* Concurrent second malignancy requiring systemic treatment, such as chemotherapy, immunotherapy, or targeted therapy\n* Clinically unstable comorbidity, including NYHA class III-IV heart failure or active systemic infection\n* Acute symptomatic thrombosis or pulmonary embolism within 4 weeks before the pretreatment D-dimer measurement\n* Incidental asymptomatic thromboembolic events detected during clinical diagnostic work-up or following an elevated D-dimer result are not exclusion criteria and will be documented\n* Physician-estimated life expectancy of less than 3 months or severe non-tumor-related comorbidity likely to preclude assessment of the clinical course within the first 6 months\n* Lack of capacity to consent or legal guardianship without valid legal representation","18 Years",{"count":60,"type":22},116,"OBSERVATIONAL","D-TECT is a prospective, multicenter, non-interventional observational study investigating whether pretreatment D-dimer levels predict disease control in patients with locally advanced or metastatic cutaneous squamous cell carcinoma treated with cemiplimab in routine clinical care.\n\nD-dimers are routinely available laboratory markers related to activation of the coagulation system. Previous single-center data suggest that elevated pretreatment D-dimer levels may be associated with poorer disease control under cemiplimab. In D-TECT, a single pretreatment D-dimer value and prospectively collected routine clinical follow-up data will be analyzed to validate this association in a multicenter real-world setting. No study-specific treatment decisions, imaging procedures, or additional blood draws are mandated by the study.",[64,65,66],"Cutaneous Squamous Cell Carcinoma (CSCC)","Advanced Cutaneous Squamous Cell Carcinoma","Metastatic Cutaneous Squamous Cell Carcinoma",[68,69,70,71,72,73,74,75,76,77],"CSCC","Cutaneous Squamous Cell Carcinoma","D-Dimer","Cemiplimab","PD-1 inhibitor","immunotherapy","biomarker","disease control","coagulation","real-word evidence","NOT_YET_RECRUITING","2026-07-21",{"date":81,"type":41},"2026-07-22",{"date":83,"type":22},"2026-08-01",{"date":85,"type":22},"2030-03-31",{"name":47,"class":48},15,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":49},"100601743","delirium-and-cognitive-impairment-development-in-hospitalized-older-adults-under-isolation-conditions-100601743","NCT07114458","Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions","Delirium Incidence and Cognitive Trajectories in Isolated Older Patients in the Inpatient Setting","DELiso","Inclusion Criteria: - hospitalized patients\n\n* under isolation precautions for at least 24h\n* 70 years and above\n\nExclusion Criteria: - no informed consent\n\n* intensive care treatment\n* life expectancy 14 days or less","70 Years",{"count":98,"type":22},404,"The goal of this observational study is to examine if older patients who need to be under isolation precautions due to multidrug resistant bacteria or other reasons have an increased risk of suffering from delirium or cognitive decline compared to older patients without isolation precautions.\n\nTo compare this, every person under isolation precautions is compared to other persons of the same age, gender, comorbidities, frailty status and hospital department. Delirium is assessed twice daily with a screening tool named 3D-CAM and cognitive performance is tested by the MOCA-Test six weeks after discharge from hospital and compared to baseline values which are assessed directly after study enrollment.\n\nThe study duration for each patient participating is from the time of enrollment during hospitalization until 6 weeks after hospital discharge.",[101,102,103],"Delirium","Dementia","Cognitive Impairment",[101,105,106,107],"neurocognitive disorder","older adult","isolation precautions",{"date":109,"type":41},"2026-07-23",{"date":111,"type":41},"2025-08-05",{"date":113,"type":22},"2027-11",{"name":47,"class":48},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":96,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":49},"100584454","comparison-of-preoperative-frailty-assessment-tools-100584454","NCT06889545","Comparison of Preoperative Frailty Assessment Tools","Evaluation of a Feasible Frailty Assessment Tool for Preoperative Risk Evaluation of Older Patients","PREFAS","Inclusion Criteria:\n\n* 70 years and older\n* scheduled surgery\n* estimated time of surgery 120 Minutes or more\n\nExclusion Criteria:\n\n* insufficient German language skills (for cognitive testing)\n* mental retardation\n* relevant psychiatric disorder (not allowing for cognitive testing)",{"count":124,"type":22},584,"Frailty is a significant risk factor for postoperative complications and functional decline. Preoperative assessment of frailty is therefore recommended in all older adults. However, despite the availability of many frailty tools, few have been tested in the preoperative setting and there is little comparison of their predictive value in identifying patients at risk. The aim of this study is to investigate which of the following instruments for determining frailty has the highest predictive power with regard to the occurrence of postoperative complications: Risk Analysis Index, Clinical Frailty Scale, the Groningen Frailty Indicator, the Edmonton Frail Scale and the LUCAS-FI. The aim of this research project is to identify a suitable frailty instrument for preoperative risk stratification of older patients during the premedication visit.",[127,128,129],"Frailty","Frailty in Older Adults","Frailty\u002FSarcopenia",{"date":81,"type":41},{"date":132,"type":41},"2025-04-15",{"date":134,"type":22},"2028-04-01",{"name":47,"class":48},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100647911","maintaining-intraoperative-mean-arterial-pressure-at-85-mmhg-or-higher-to-reduce-postoperative-delirium-in-older-patients-with-arterial-hypertension-having-non-cardiac-surgery-100647911","NCT07713121","Maintaining Intraoperative Mean Arterial Pressure at 85 mmHg or Higher to Reduce Postoperative Delirium in Older Patients With Arterial Hypertension Having Non-cardiac Surgery","Maintaining Intraoperative Mean Arterial Pressure at 85 mmHg or Higher to Reduce Postoperative Delirium in Older Patients With Arterial Hypertension Having Non-cardiac Surgery: the Multicenter Randomized ASPIRE-85 Trial","ASPIRE-85","Inclusion Criteria:\n\nTo be eligible for trial inclusion, patients must:\n\n* 1\\) be able to provide informed consent, AND\n* 2\\) be ≥65 years old, AND\n* 3\\) be scheduled for elective non-cardiac surgery with general anesthesia that is expected to last ≥120 minutes, AND\n* 4\\) have chronic arterial hypertension requiring antihypertensive medication OR have a systolic arterial pressure ≥140 mmHg or diastolic arterial pressure ≥90 mmHg on a measurement performed within the previous year, AND\n* 5\\) be at high risk for postoperative delirium because: American Society of Anesthesiologists physical status class III or IV OR Charlson Comorbidity Index ≥3 points (please see Appendix 1) OR frailty (documented in medical records or clinical diagnosis)\n\nExclusion Criteria:\n\nPatients that meet one or more of the following exclusion criteria cannot participate in the trial:\n\n* solid organ transplant surgery\n* intracranial surgery\n* surgery in sitting position\n* sepsis\n* surgery in the previous 30 days\n* previous participation in ASPIRE-85","65 Years",{"count":146,"type":22},3432,[25],"In older patients having surgery, postoperative delirium (an acute disturbance in awareness, attention, or cognition) is common and associated with short-term and long-term morbidity and mortality. The pathophysiology of postoperative delirium is multifactorial - but presumably includes inadequate brain perfusion during surgery caused by low intraoperative blood pressure. Therefore, the investigators aim to determine in a multicenter randomized-controlled trial if targeted intraoperative blood pressure management reduces postoperative delirium. The investigators will test the primary hypothesis that maintaining intraoperative mean arterial pressure at 85 mmHg or higher - compared to at 65 mmHg or higher (routine care) - reduces the incidence of postoperative delirium within the first 3 postoperative days in older patients with arterial hypertension having non-cardiac surgery. The investigators will also assess the duration of postoperative delirium, postoperative complications, and the patients' quality of life. The results of this trial will have a direct impact on guidelines and will help improve medical care for patients and the patients' health. Effective strategies to prevent postoperative delirium are missing. The hypothesis that targeted intraoperative blood pressure management can help reduce postoperative delirium is supported by previous observational studies and interventional trials. This trial is supposed to confirm the causal relationship between intraoperative blood pressure and postoperative delirium and to demonstrate the effectiveness of the therapeutic approach.",[150,151],"Postoperative Delirium (POD)","Intraoperative Hypotension",[153,154,155],"anesthesia","cardiovascular dynamics","hemodynamic monitoring","2026-07-17",{"date":158,"type":41},"2026-07-20",{"date":83,"type":22},{"date":161,"type":22},"2030-09",{"name":47,"class":48},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":18,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":49},"100592448","analysis-of-safety-and-tissue-interaction-of-injectable-biosmulators-100592448","NCT06993558","Analysis of Safety and Tissue Interaction of Injectable Biosmulators","Analysis of Safety and Tissue Interaction of Injectable Biosmulators.","Biostimulation","-Inclusion Criteria:\n\nMen and women aged 30 years and older\n\nGood general health, no relevant pre-existing conditions\n\nPatients planning to undergo PLLA or CAHA treatment as part of routine care due to skin laxity or volume loss\n\nCognitive ability and willingness to provide informed consent\n\nWillingness and ability to attend follow-up visits\n\n-Exclusion Criteria:\n\nAge under 30 years\n\nPregnant or breastfeeding individuals\n\nSignificant open wounds or lesions in the treatment area\n\nMetallic implants in the treatment area\n\nPsychiatric disorders (psychosis, body dysmorphic disorders)\n\nMissing informed consent and\u002For data privacy declarations",true,"30 Years",{"count":174,"type":22},90,[25],"The goal of this clinical trial is to analyse tissue changes in the pre-auricular region after injectable (Poly-L-Lactic-Acid\u002FCalcium-Hydroxylapatit) biostimulatory interventions in healthy volunteers. The main questions it aims to answer are:\n\nHow is the Safety Profile of injectable Biostimulatory Treatments? How are the Tissue Interactions after injectable Biostiomulatory Treatments?\n\nParticipants will:\n\n* Recieve one of 2 possible biostumulatory treatments (PLLA\u002FCAHA\u002F\n* Attend 4 follow-up appointments after treatment for checkups, surveillance and examinations.",[178],"This Study Aims to Evaluate the Safety Profile and Tissue Changes After Biostimulatory Treatments to the Face in Healthy Volunteers",[180,169,181,182],"Ultrasound","Poly-L-Lactic-Acid","Calcium-Hydroxylapatit","2026-07-13",{"date":185,"type":41},"2026-07-15",{"date":187,"type":41},"2025-07-31",{"date":189,"type":22},"2027-09-15",{"name":47,"class":48},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":198,"maxAge":58,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":49},"100593675","early-phase-1-hands-on-emotion-awareness-and-regulation-group-training-for-autistic-adolescents-heart-100593675","NCT07009522","Hands-on Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART)","HEART","Autistic adolescents will be included in the study, recruited from various departments of the Clinic for Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics at UKE, as well as from autism therapy centers. Eligible participants are adolescents aged 13 to 18 years who meet the criteria for a primary diagnosis of an autism spectrum disorder-including early childhood autism (ICD-10: F84.0), atypical autism (ICD-10: F84.1), and Asperger's syndrome (ICD-10: F84.5)-and who have sufficient knowledge of the German language. The diagnosis should be confirmed based on developmental history, the ADOS-2 assessment, and a clinical diagnosis from a specialized clinician. Additionally, only autistic adolescents exhibiting difficulties in emotion regulation (measured by the Emotion Regulation Inventory (EDI-SF), T-score ≥ 60) will be included. Exclusion criteria are: below-average cognitive abilities, IQ ≤ 85 (ICD-10: F70); lack of German language skills; or significant visual or hearing impairments that cannot be corrected. Furthermore, patients with severe neurological or psychiatric conditions (e.g., epilepsy, syndromic disorders with neuropsychiatric involvement, psychoses) or current acute suicidality, as assessed clinically, will be excluded.","13 Years",{"count":200,"type":22},21,[202],"EARLY_PHASE1","The study focuses on a group training program called HEART aimed at helping adolescents with Autism Spectrum Disorder improve emotional regulation. It will use a pilot trial to evaluate the program's feasibility and effectiveness. The findings aim to advance scientific understanding and support the development of effective, evidence-based interventions to strengthen psychosocial support for autistic adolescents.",[205],"Study Group","2026-07-12",{"date":208,"type":41},"2026-07-14",{"date":210,"type":41},"2026-01-15",{"date":212,"type":22},"2027-02-15",{"name":47,"class":48},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},"100646941","phase-4-spontaneous-coronary-artery-dissection---antiplatelet-therapy-intensity-in-guided-conservative-management-scad-align-trial-100646941","NCT07683923","Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial","Spontaneous Coronary Artery Dissection - Antiplatelet Therapy Intensity in Guided Conservative Management (SCAD-ALIGN) Trial","SCAD-ALIGN","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Presentation with an Acute Coronary Syndrome.\n3. Suspected SCAD on coronary angiography (determined by the local investigator).\n4. Planned conservative treatment of SCAD.\n5. Intensive as well as moderate treatment of SCAD is possible.\n6. Ability to understand the patient information and to personally sign and date the informed consent to participate in the study, before completing any study-related procedures.\n7. The patient is cooperative and available for the entire study.\n8. Written and informed consent.\n9. For women of childbearing potential: Patient is willing to use adequate contraceptive precautions during the study (until 12 Month FU)\n\nExclusion Criteria:\n\n1. Hypersensitivity to the study medication.\n2. Any indication for oral anticoagulation.\n3. Any indication for APT (including thienopyridines, non-thienopyridines, ASA and other anti-thrombotic agents) other than SCAD.\n4. Cardiogenic shock at the time of screening.\n5. Coronary artery disease (CAD) requiring secondary preventive therapy with APT.\n6. Life threatening bleeding (BARC type ≥3) at the time of screening.\n7. Active bleeding, such as peptic ulcer, tumor bleeding or intracranial hemor-rhage at the time of screening.\n8. History of major bleeding, BARC class ≥3 within 3 months before study in-clusion.\n9. Known bleeding diathesis.\n10. Known coagulopathy or refusal of blood transfusion.\n11. Planned surgery or intervention at high bleeding risk during the study period.\n12. Co-administration of contraindicated medications as follows: other P2Y12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral antico-agulants, or chronic therapy with subcutaneous anticoagulants); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg\u002Fweek); lithium.\n13. Known pregnancy or lactation.\n14. Current participation in another clinical trial with drugs or medicinal products.",{"count":223,"type":22},3518,[225],"PHASE4","Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome in which blood flow to the heart muscle is reduced or interrupted. It predominantly affects women between 30 and 55 years of age and typically occurs in the absence of atherosclerosis. For many years, SCAD remained underdiagnosed and has only recently been more systematically recognised. The SCAD-ALIGN trial will be the first randomised study to systematically compare two antiplatelet treatment strategies in patients with SCAD.\n\nSCAD is usually not associated with significant atherosclerosis or the classic vessel occlusion caused by a blood clot. Instead, bleeding occurs within the wall of a coronary artery, causing the vessel layers to separate and thereby impairing or completely obstructing blood flow. Patients develop symptoms of acute myocardial infarction, such as chest pain, shortness of breath, or nausea. A characteristic feature is that these symptoms often occur in individuals without a prior history or risk of heart disease.\n\nPlatelets play a crucial role in blood clotting but can also accumulate inside blood vessels and further impair flow. Antiplatelet medications are used to prevent this. In current clinical practice, SCAD patients are often treated according to general guidelines for acute coronary syndrome, which typically include two different antiplatelet therapies, a strategy developed and tested in older patients with proven atherosclerosis.\n\nThe SCAD-ALIGN trial is based on a fundamental difference between SCAD and classic heart attacks. In typical heart attacks, a blood clot usually blocks a vessel, and after the implantation of a vascular support device (\"stent\"), intensive antiplatelet therapy is used to prevent further clot formation. In SCAD, however, the underlying problem is a tear or bleeding within the vessel wall. In this situation, intensive antiplatelet therapy could delay the resolution of the bleeding or even worsen it, thereby adversely affecting the course of the disease. The study will therefore investigate whether a less intensive treatment strategy may be more beneficial in these patients.\n\nThe SCAD-ALIGN trial compares two treatment strategies: moderate antiplatelet therapy with a single medication for three months versus more intensive therapy with two agents for three months, followed by nine months of treatment with a single medication. The primary endpoint is a composite of recurrent myocardial ischemia, recurrent SCAD, myocardial infarction, the need for revascularization, and death.\n\nThe SCAD-ALIGN trial is part of the Multinational Clinical Trials Initiative of the Global Cardiovascular Research Funders Forum (GCRFF). The study is designed as an international, multicentre, randomised, open-label clinical trial. Because SCAD is a rare condition, close collaboration across national borders is essential. The results are expected to make an important contribution to the development of evidence-based treatment recommendations for SCAD, improve care and quality of life for patients worldwide.",[228,229],"SCAD","ACS (Acute Coronary Syndrome)",[228,231,232,233,234,235,236],"ACS","APT","MACE","DAPT","spontaneous coronary artery dissection","Antiplatelet therapy","2026-06-28",{"date":239,"type":41},"2026-07-06",{"date":241,"type":22},"2027-03-01",{"date":243,"type":22},"2033-02-28",{"name":47,"class":48},5,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":49},"100564767","adolescent-psychiatry-inpatients-self-reported-parent-adolescent-communication-quality-and-treatment-outcome-100564767","NCT06633458","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality and Treatment Outcome","Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality as a Predictor of Treatment Outcome","Inclusion Criteria:\n\n* Admission to inpatient care unit of the adolescent psychiatry at the University Medical Center Hamburg-Eppendorf.\n\nExclusion Criteria:\n\n* Severe symptom burden at admission\n* Lack of knowledge of the German language.","14 Years","17 Years",{"count":256,"type":22},60,"The quality of parent-adolescent communication has been found to be associated with adolescent mental health. However, little is known about the association of parent-adolescent communication and adolescent mental health in the context of psychiatry inpatient treatment.\n\nThis study aims to find out whether self-reported parent-adolescent communication quality at the time of admission to psychiatry predicts the treatment outcome in terms of symptom reduction 6 months later in an adolescent inpatient sample. It also aims to track changes in adolescent self-reported communication quality in the course of inpatient treatment and afterwards (2, 4 and 6 months after admission) to see whether improvement predicts treatment outcome, with treatment outcome being defined as symptom reduction to baseline. As a secondary endpoint, it will be assessed whether a placement of the adolescent outside the family was considered during treatment and whether self-reported communication quality at the time of admission predicts the consideration of placement outside the family.",[259,260,261],"Mental Disorder in Adolescence","Depression in Adolescence","Anxiety",[263,264,265],"mental health","adolescence","communication",{"date":267,"type":41},"2026-07-01",{"date":269,"type":41},"2024-07-08",{"date":271,"type":22},"2027-10-30",{"name":47,"class":48},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":281,"targetDuration":172,"studyType":61,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":49},"100427656","the-patients-presenting-with-congenital-heart-disease-register-artoria-r-100427656","NCT04848844","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart\u002FLung Transplantation","ARTORIA-R","Inclusion Criteria:\n\n1. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years\n2. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD\n3. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation\n4. Transfer of anonymised data\n5. The institution\u002Forganization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions\n\nExclusion Criteria:\n\na. The patient is listed for a second heart transplantation (retransplantation)",{"count":282,"type":22},2000,"Advances in surgical and medical care have led to improved outcomes in patients with congenital heart disease (CHD). As a consequence, the majority of patients nowadays survives to adulthood (adults with CHD, that is, adult CHD \\[ACHD\\]) with good quality of life. Despite the surgical success, the morbidity and mortality of ACHD is higher than in the general population and is linked to the development of heart failure (HF) in adulthood.\n\nHF occurs in approximately 25% of patients with ACHD, even in those patients in whom the congenital mal-formation has been corrected successfully in childhood. The time course and presentation are heterogeneous owing to variable congenital malformation and limitation of treatment options. ACHD with an anatomic right ventricle as the systemic ventricle (e.g., atrial switch operation in patients with transposition of the great arteries \\[TGAs\\]) and those with a functional single ventricle (e.g., Fontan circulation) appear to be at higher risk of developing HF. Young age at initial corrective surgery-often in the first 2 years of life-and lack of specific medical therapies can contribute to a high and early demand for heart transplantation in patients with ACHD.",[285,286,287,288,289],"Congenital Heart Disease","Heart Failure","Transplant; Complication, Failure","Arrythmia","Ventricular Dysfunction",{"date":267,"type":41},{"date":292,"type":41},"2020-09-02",{"date":294,"type":22},"2030-07-30",{"name":47,"class":48},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":304,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100634338","continuous-versus-bolus-norepinephrine-administration-to-treat-postinduction-hypotension-100634338","NCT07538388","Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension","Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension in High-Risk Non-Cardiac Surgery Patients - The Multicenter INDUCT Trial (INDUCT-Multi)","INDUCT-Multi","Inclusion Criteria:\n\nWe will include consenting patients ≥45 years scheduled for elective non-cardiac surgery under general anesthesia with planned continuous intra-arterial blood pressure monitoring with a radial arterial catheter and with at least two of the following risk criteria for developing acute kidney injury:\n\n* Age ≥65 years\n* ASA physical status III or IV\n* Chronic arterial hypertension\n* Diabetes mellitus requiring medication\n* Intra-abdominal surgery\n* Preoperative renal insufficiency (serum creatinine ≥1.2 mg\u002FdL)\n\nExclusion Criteria:\n\n* Pregnancy\n* Cardiac arrhythmia\n* History of intracranial hemorrhage or intracranial aneurysm\n* Clinical indication for continuous norepinephrine infusion during induction of general anesthesia (e.g., severe aortic valve stenosis, coronary artery disease, or heart failure)\n* Patients who are unable to understand, read, and provide informed consent in German","45 Years",{"count":306,"type":22},446,[25],"INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients.",[310],"Postinduction Hypotension",[312,313,314,315,316,317],"postinduction hypotension","non-cardiac surgery","norepinephrine","bolus","hypotension","continuous","2026-06-24",{"date":320,"type":41},"2026-06-29",{"date":322,"type":41},"2026-05-07",{"date":324,"type":22},"2026-12",{"name":47,"class":48},4,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":171,"sex":18,"minAge":58,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":49},"100638644","positive-expectation-effects-on-early-emotional-processing-100638644","NCT07615530","Positive Expectation Effects on Early Emotional Processing","Inclusion Criteria:\n\n* Aged 18-35 years\n* Normal or corrected to normal vision\n* Signed declaration of consent\n* German speaking\n\nExclusion Criteria:\n\n* No informed consent\n* Current intake of central nervous system active drugs\n* Under influence of alcohol\n* BDI score above 12\n* Significant acute somatic or neurological diseases\n* History of psychiatric or neurological disorders\n* Acute nasal diseases or injuries\n* EEG data with strong artefacts or excessive movement will be excluded from analysis\n* If a participant does not believe in the treatment on the screening day, they will not be included for the main study days","35 Years",{"count":335,"type":22},51,[25],"Insights into the mechanisms of expectation effects in the emotional domain can be invaluable for the development of potential therapeutic interventions for mood disorders. Recent findings demonstrate that positive expectations alone can induce a positivity bias on the behavioral and the neural level (Baker et al.,2022, Mostauli et al., 2025). This is intriguing given that antidepressant treatments, which have high placebo rates are reported to reduce a negativity bias commonly observed in depression.\n\nResearch on placebo analgesia has shown that both higher-order cognitive expectations and lower-level learning mechanisms, such as conditioning, play a key role in placebo effects. The role of such lower-level processes is particularly underexplored in affective placebo effects. Closing this gap is crucial, as the long-term modulation of the emotional system likely depends on cognitively less demanding, bottom-up processes shaped by learning and conditioning. This is particularly relevant in clinical populations, where cognitive resources may be limited, but there is an abundance of prior experiences (i.e., learning).\n\nThe present study therefore investigates how treatment expectations influence early psychophysiological processing of emotional stimuli. Beyond behavioral measures, we will directly assess early neural and attentional mechanisms using sensory event-related potentials (ERPs) and reflexive gaze shifts. By combining EEG and eye-tracking, we aim to identify early markers of expectation effects during emotional processing in healthy participants (N=44 plus 15% potential dropout, 50% women), who perform an emotion classification task. Emotional faces will be presented at varied levels of stimulus visibility (alpha transparency), allowing us to model perceptual sensitivity and response bias without inducing ceiling effects.\n\nTreatment expectation will be induced by verbal instructions using an established protocol (e.g. Baker et al., 2022, Mostauli et al., 2025). We hypothesize that positive expectations enhance mood and decrease reaction times paralleled by better accuracy. Further, we hypothesize that positive treatment expectation enhances gaze shifts toward the mouth region which is the primary diagnostic feature for happy faces. On the neural level we expect that positive expectations modulate EEG signal patterns associated with early emotional valence processing. Additionally, whole-brain and time-frequency analyses, as well as representational similarity analyses, are planned to further explore into neural expectation effects and potential changes in the hierarchical representation of emotional processing.",[339],"Positive Expectations",[341,342,343,344,345,346],"Treatment expectation","EEG","Eye Tracking","Emotional processing","Placebo","Positive expectation","2026-05-29",{"date":349,"type":41},"2026-06-02",{"date":351,"type":22},"2026-06",{"date":324,"type":22},{"name":47,"class":48},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":49},"100639133","phase-1-etenta-isa-vrd-in-newly-diagnosed-high-risk-multiple-myeloma-100639133","NCT07600151","Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma","A Clinical Phase I\u002FII, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients","CONQUISTADOR","Inclusion Criteria:\n\n* Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.\n* Participants must have High-risk myeloma according to IMS\u002FIMWG CGS\n* Participants must be considered a candidate for high-dose chemotherapy and ASCT, as described in the protocol.\n* Participants must have measurable disease as defined in the protocol. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions).\n* Participants must have clinical laboratory values within a prespecified range.\n\nExclusion Criteria:\n\n* Known contraindications to the use of any IMP or axMP or required concomitant drugs or supportive treatment.\n* known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia\n* Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma first-line treatment within the specifications of the protocol\n* known central nervous system involvement by MM.",{"count":363,"type":22},220,[365,366],"PHASE1","PHASE2","This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.",[369,370],"Myeloma Multiple","Myeloma","2026-05-14",{"date":373,"type":41},"2026-05-20",{"date":45,"type":22},{"date":376,"type":22},"2036-12-31",{"name":47,"class":48},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":245},"100504871","phase-1-combination-treatment-of-belantamab-mafodotin-and-venetoclax-in-treatment-of-relapsed-and-refractory-t1114-multiple-myeloma-100504871","NCT05853965","Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma","Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I\u002FIIa) The BELI(E)VE-Trial","BELI(E)VE","Relapsed and refractory t(11;14) Multiple Myeloma (RRMM)\n\nInclusion criteria:\n\n1. Subjects must be ≥ 18 years of age.\n2. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n3. Subjects must voluntarily sign and date an in-formed consent form\n4. Subjects must have had documented multiple myeloma requiring treatment as defined by the criteria below:\n\n   Monoclonal plasma cells in the bone marrow \\> 10% and\u002For presence of a biopsy proven plasmacytoma at some point in their disease history requiring treatment according diag-nostic criteria (IMWG updated criteria 2014, Rajkumar et al. 2014) with measurable dis-ease at screening (serum M-protein \\> 500 mg\u002FdL or urine M protein 200 mg\u002F24h, in case of oligosecretory MM serum free light chain \\> 10mg\u002FdL and abnormal kap-pa\u002Flambda free light chain ratio)\n5. Cytogenetics\u002FFISH confirming t(11;14)\n6. Prior treatment requirements:\n\n   Prior treatment requirements:\n\n   a. Subjects must have received at least 1 prior treatment line (induction, high-dose, consolidation and maintenance is considered as one treatment line). All patients have to have received at least one proteasome inhibitor and at least one immunomodulatory agent and at least one anti-CD38 monoclonal antibody.\n\n   b. Subjects must have documented evidence of progressive disease on or after the last treatment line.\n\n   c. Subjects with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: i. ASCT was \\>100 days prior to initiating study treatment, and ii. No active bacterial, viral, or fungal in-fection(s) present.\n7. Subjects must have adequate organ function, defined as follows:\n\n   a. Hemoglobin ≥8.0 g\u002FdL (without transfusion of red blood cells for the past 14 days) b. Absolute neutrophil count ≥ 1.5 x109\u002FL (with-out growth factor support for the past 14 days) c. Platelet count more or equal 75 x109\u002FL (with-out growth factor or platelet stimulating agents for the past 14 days) d. Adequate hepatic function per local laborato-ry reference range as follows: i. Aspartate aminotransferase (AST) ≤ 2,5 x upper limit of normal (ULN); ii. Alanine aminotransferase (ALT) ≤ 2.5 x ULN iii. Total bilirubin ≤ 1.5 x ULN, except in subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bili-rubin ≤ 1.5 x ULN). Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C35%.\n\n   e. Subjects must have adequate renal function as demonstrated by eGFR ≥30 mL\u002Fmin\u002F 1.73 m2 as calculated by Modified Diet in Renal Disease (MDRD) formula f. Spot urine (albumin\u002Fcreatinine ratios (spot urine) \\\u003C500 mg\u002Fg (56 mg\u002Fmmol) OR Urine Dipstick Negative\u002Ftrace (if 1+ only eligible if confirmed \\\u003C500 mg\u002Fg (56 mg\u002Fmmol) by albumin\u002Fcreatinine ratio (spot urine from first void) g. Corrected serum calcium ≤ 14 mg\u002FdL (≤3,5 mmol\u002FL); or free ionized calcium ˂ 6,5 mg\u002FdL (˂1,6 mmol\u002FL)\n8. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   1. Is not a woman of childbearing potential (WOCBP) OR\n   2. Is a WOCBP and using a contraceptive method that is highly effective\n9. Male participants are eligible to participate if they agree to the refrain from donating sperm and either bei abstinent from heterosexual intercourse or agree to use a highly effective contraceptive method during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm\n10. All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment.\n11. All subjects must agree not to share study medication.\n12. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be ≤ Grade 1 at the time of en-rolment except for alopecia.\n\nExclusion Criteria:\n\n1. Subject has received prior Venetoclax and\u002For anti BCMA treatment.\n2. Participant has used an investigational drug or approved systemic anti-myeloma therapy with-in 14 days or five half-lives, whichever is short-er, preceding the first dose of study drug. The only exception is emergency use of a short course of corticosteroids (equivalent of Dexa-methasone 40 mg\u002Fday for a maximum of 4 days) up to 7 days before treatment.\n3. Participant has had plasmapheresis or radia-tion therapy within 7 days prior to first dose of study treatment\n4. Participant has current corneal epithelial dis-ease except mild changes in corneal epitheli-um\n5. Participant has current unstable liver or biliary disease\n6. Participant has a presence of active renal con-dition (infection, requirement for dialysis or any other condition that could affect participant's safety).\n7. Participant has had major surgery ≤ 4 weeks prior to initiating study treatment. Kyphoplasty is not considered a major surgery.\n8. Participant must not use contact lenses while participating in this study. Bandage contacts may be prescribed by an eye care professional if needed.\n9. Participant has any evidence of active mucosal or internal bleeding or other gastrointestinal disease that may significantly alter the absorp-tion of oral drugs.\n10. Participant has evidence of cardiovascular risk as defined in the protocol\n11. Participant has known immediate or delayed hypersensitivity reaction or idiosyncratic reac-tions to IMPs or drugs chemically related to IMPs, or any of the components of the study treatment\n12. Participant has an invasive malignancy other than disease under study within 5 years before trial inclusion, except\n\n    * Adequately treated in situ carcinoma of the cervix uteri or the breast;\n    * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n    * Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment;\n    * Previous malignancy with no current evi-dence of disease, and which was confined and surgically resected (or treated with other mo-dalities) with curative intent and unlikely to im-pact survival during the duration of the study.\n13. Participant is pregnant or lactating\n14. Participants who have had prior allogeneic stem cell transplant.\n15. Participants with symptomatic amyloidosis, ac-tive POEMS syndrome (polyneuropathy, or-ganomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes) or active plasma cell leukaemia at the time of screening.\n16. Participants with any serious and\u002For unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, ob-taining informed consent or compliance to the study procedures.\n17. Subject is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B sur-face antigen (HBsAg) or antibodies to hepatitis B surface and core antigen (anti HBs and anti HBc respectively), or hepatitis C (anti-HCV an-tibody positive or HCV RNA quantitation posi-tive).\n18. Current immune or inflammatory conditions re-quiring immunosuppressive treatment (e.g. systemic lupus erythematosus, rheumatoid ar-thritis).\n19. Subject must not have received any live vac-cines within 8 weeks prior to first dose of study treatment.\n20. Subject must not use or anticipate the use of prohibited medications or foods during study participation.\n21. Subject does not have a history of or show any signs of known meningeal\u002Fcentral nervous sys-tem involvement by myeloma.\n22. Evidence of other clinically significant uncon-trolled condition(s) that is likely to interfere with the study proce-dures or results, or that in the opinion of the investigator, would constitute a hazard for the participation in this study.\n23. Subject is known or suspected of not being able to comply with the study protocol. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit or confound the pro-tocol-specified assessments.\n24. Treatment with any of the following within 7 days prior to the first dose of study drug:\n\n    1. moderate or strong cytochrome P450 3A (CYP3A) inhibitors\n    2. moderate or strong CYP3A inducers\n25. Administration or consumption of any of the fol-lowing within 3 days prior to the first dose of study drug:\n\n    1. grapefruit or grapefruit products\n    2. Seville oranges (including marmalade con-taining Seville oranges)\n    3. star fruit\n26. Participation in any other clinical trial (with the exclusion of observational studies)",{"count":387,"type":22},45,[365,366],"The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed\u002Frefractory multiple myeloma bearing the translocation t(11;14)",[391,392],"Multiple Myeloma","Multiple Myeloma in Relapse",[394,395,396,397],"t(11;14)","venetoclax","belantamab mafodotin","multiple myeloma",{"date":399,"type":41},"2026-05-18",{"date":401,"type":41},"2023-06-28",{"date":403,"type":22},"2028-12",{"name":47,"class":48},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":49},"100461778","phase-3-early-treatment-of-atrial-fibrillation-for-stroke-prevention-trial-in-acute-stroke-100461778","NCT05293080","Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","EAST-STROKE","Inclusion Criteria:\n\n* Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis\n* Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable\n* AF first detected ≤1 year prior to randomization\n* Informed consent\n\nExclusion Criteria:\n\n* End-stage cancer or life-expectancy \\\u003C 12 months due to other advanced co-morbid illness\n* Prior AF ablation or surgical therapy of AF\n* Patients not suitable for rhythm control of AF due to cardiac conditions",{"count":413,"type":22},1746,[415],"PHASE3","This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.",[418,419],"Acute Ischemic Stroke","Atrial Fibrillation",[421,422,423,424,425],"Acute ischemic stroke","Atrial fibrillation","Rhythm control","Ablation","Antiarrhythmic drugs",{"date":399,"type":41},{"date":428,"type":41},"2025-11-06",{"date":430,"type":22},"2031-09",{"name":47,"class":48},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":454},"100415327","choice-of-optimal-transcatheter-treatment-for-mitral-insufficiency-registry-100415327","NCT04688190","CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry","Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry","CHOICE-MI","Inclusion Criteria:\n\n* clinically significant mitral insufficiency\n* patient underwent screening for TMVI\n* echocardiography data at baseline (and after TMVI, E2E and surgery)\n* follow-up of at least 30 days\n\nExclusion Criteria:\n\n\\- age under 18 years",{"count":441,"type":22},1000,"This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice.\n\nPatients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical\u002Fconservative therapy.",[444,445,446],"Mitral Regurgitation","Mitral Valve Disease","Mitral Annular Calcification","2026-05-03",{"date":322,"type":41},{"date":450,"type":41},"2020-11-01",{"date":452,"type":22},"2030-12-31",{"name":47,"class":48},43,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":49},"100573028","imaging-and-serological-biomarkers-of-autonomic-dysfunction-after-ischemic-stroke-100573028","NCT06740942","Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke","ARIADNE","Inclusion Criteria:\n\n* Diagnosis of either\n\n  * acute ischemic stroke with either an ischemic lesion visible on CT\u002FMRI or persistent focal deficits 24 hours after symptom onset, or\n  * Transient ischemic attack with transient clinical deficits including motor or speech disturbance and not restricted to isolated vertigo\u002Fdizziness, visual disturbance, or sensory disturbance.\n* symptom onset within 72h prior to hospital admission,\n* a pre-stroke\u002FTIA ability to walk without help from another person (modified Rankin scale score \\\u003C 4),\n* age \\> 18 years, and\n* informed consent by either the patient or a legal representative (including a spouse)\n\nExclusion Criteria:\n\n* In-hospital stroke,\n* contraindications to MR imaging (e.g., claustrophobia, pregnancy, pacemakers, implants),\n* known moderate to severe dementia,\n* previous structural brain damage (except leukoariosis due to cerebral small vessel disease),\n* hemodynamically relevant stenosis of the common or internal carotid artery, or\n* left heart failure with estimated left ventricular ejection fraction \\\u003C 50%,\n* concomitant systemic illness that can lead to dysautonomia, such as an active infection, thyroid disease, or neurodegenerative disorder (e.g. PD, MSA).",{"count":463,"type":22},100,"The goal of this observational study is to\n\n* to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients;\n* to evaluate the influence of lesion location on autonomic dysfunction;\n* to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and\n* to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia.\n\nResearchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions.\n\nParticipants will\n\n* undergo cardiovascular autonomic function testing;\n* receive structural and functional MR imaging;\n* provide blood samples for determinaton of serological biomarkers auf dysautonomia.",[418,466],"Transient Ischemic Attack",[468,469,470,471,472,473,474,475,476,477,478,479,480,481],"Autonomic dysfunction","cardiovascular dysregulation","brain-heart axis","stroke-heart syndrome","acute ischemic stroke","transient ischemic attack","autonomic function test","central autonomic network","network lesion mapping","lesion symptom mapping","resting-state fMRI","functional brain network","structural brain network","diffusion tensor imaging","2026-05-01",{"date":322,"type":41},{"date":485,"type":41},"2025-08-04",{"date":324,"type":22},{"name":47,"class":48},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":49},"100592449","cerebellar-transcranial-alternating-current-stimulation-tacs-to-modulate-parkinsons-disease-tremor-100592449","NCT06993571","Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor","Closed-loop Phase-adaptive Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Activity in the Cerebello-thalamo-cortical Network to Reduce Parkinson's Disease Tremor","tACS_PD_TR","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's disease based on UK Brain Bank criteria\n* Patient exhibiting moderate to severe hand tremor\n* Provision written informed consent by the patient\n\nExclusion Criteria:\n\n* History of other neurological disorders such as vascular malformations, ischemic or haemorrhagic stroke, cerebral neoplasia, epilepsy, or major psychiatric illness\n* Existence of heart pacemaker or metal implants in the body\n* Pregnancy",{"count":497,"type":22},10,[25],"Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by different motor symptoms, including tremor, which is particularly difficult to manage. Common treatments, such as dopaminergic therapy, can have limitations in efficacy. Recent advancements in non-invasive brain stimulation, specifically phase-adaptive transcranial alternating current stimulation (tACS), offer a promising approach to reduce PD tremor. In the current project, a newly developed closed-loop system delivers precisely synchronized cerebellar tACS by aligning stimulation with the intrinsic hand tremor signal. The study will assess the efficacy of this novel approach to reduce hand tremor in PD patients.",[501,502],"Parkinson's Disease (PD)","Tremor",[504,505,506,507,508,509,510],"Parkinson's disease","Hand tremor","Transcranial alternating current stimulation","Non-invasive brain stimulation","Closed-loop stimulation","Phase-adaptive stimulation","Tremor entrainment","2026-04-28",{"date":513,"type":41},"2026-05-04",{"date":515,"type":41},"2025-04-16",{"date":517,"type":22},"2026-12-31",{"name":47,"class":48},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":49},"100587711","awake-prone-positioning-in-spontaneous-breathing-patients-with-acute-hypoxic-respiratory-failure-due-to-pneumonia-100587711","NCT06931938","Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia","Awake PROne Positioning in PatientS With Acute Hypoxemic Respiratory Failure in Germany - A Randomized Controlled Study","PROSA","Inclusion Criteria:\n\n* The focus of this trial is to treat patients with respiratory failure. The inclusion criteria are selected accordingly. Patients meeting all of the criteria listed below will be included in the study:\n\n  * Patients in the intensive care unit\n  * High possibility of Pneumonia (community-acquired pneumonia or hospital-acquired pneumo-nia) either diagnosed by chest x-ray or computed tomography or clinically diagnosed at least with one of the following signs\n\n    * Appearance of purulent secretions or changes in characteristics (color, odor, quantity, consistency)\n    * Cough or dyspnea or tachypnea\n    * Evocative auscultation\n  * Presence of acute hypoxemic respiratory failure (PaO2\u002FFIO2 ≤ 300 mmHg or SpO2\u002FFiO2 ≤ 315)\n\nExclusion Criteria:\n\n* Patients are excluded from the study if any of the following criteria are met at screening or before ran-domization, a detailed list is shown in the study manual:\n\n  * Age below 18\n  * Pregnant woman\n  * Patient is unlikely\u002Funable to awake prone positioning, or to be compliant as indicated by the treating team\n  * Prolonged need (≥ 4 days) for HFNO, NIV or CPAP before study inclusion\n  * Urgent need for endotracheal intubation\n  * Invasive Mechanical Ventilation\n  * Shock\n\n    o Defined as need for vasopressor ≥ 0.4 mcg\u002Fkg\u002Fmin to maintain a mean blood pressure of ≥ 65 mmHg or systolic blood pressure ≥ 90 mmHg\n  * Participation in another clinical interventional trial in the last 3 months\n  * Previous Participation in the PROSA Trial\n  * Long-term oxygenation therapy (LTOT) or continuous positive airway pressure (CPAP) therapy before hospital admission\n  * Treatment",{"count":528,"type":22},342,[25],"Prone positioning has shown beneficial effects in intubated patients with severe respiratory failure and positive effects in awake patients with COVID-19 pneumonia. Conclusive evidence for patients with AHRF without COVID-19 is still missing. The investigators hypothesis that awake prone position in patients with AHRF is superior to standard supine\u002Fsemi-recumbent position in terms of reducing the rate of tracheal intubation and\u002For all-cause death within 28 days after randomization.",[532],"Acute Hypoxemic Respiratory Failure",{"date":513,"type":41},{"date":535,"type":41},"2025-04-11",{"date":537,"type":22},"2027-06-30",{"name":47,"class":48},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":49},"100636352","physical-activity-directly-before-immunotherapy-nivolumab-and-ipilimumab-in-melanoma-100636352","NCT07564570","Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma","SPRINT - Short Moderate Physical Regime INtervention Directly Before ImmunoTherapy for Melanoma","SPRINT","Inclusion Criteria:\n\n* Histologically confirmed metastatic malignant melanoma with an indication for immunotherapy (Nivolumab and Ipilimumab).\n* The participant provides written informed consent for the study.\n* The participant is at least 18 years of age on the day the informed consent is signed.\n* No prior systemic anticancer therapy for metastatic disease (e.g., cytotoxic or targeted agents).\n* ECOG (Eastern Cooperative Oncology Group) performance status score of ≤ 2.\n* No physical impairment that would preclude participation in physical exercise.\n\nExclusion Criteria:\n\n* Major surgery within 2 weeks prior to the start of the study intervention, or participants who have not fully recovered from the effects of a previous surgery.\n* Participants with a diagnosed immunodeficiency, or those receiving chronic systemic corticosteroid therapy (at a dose greater than 10 mg prednisone equivalent per day), or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study medication.\n* Participants with an active infection requiring systemic therapy.\n* Participants with a known history of infection with human immunodeficiency virus (HIV) or hepatitis.",{"count":548,"type":22},40,[25],"The aim of this research project is to determine whether a short bout of physical exercise immediately before the start of immunotherapy (Nivolumab and Ipilimumab) is feasible and has a positive effect on the effectiveness of immunotherapy. It is known that short-term physical exercise leads to marked changes in the innate and adaptive immune system. These changes-specifically an increase in natural killer (NK) cells and cytotoxic T cells-are associated with a better response to immunotherapy.\n\nThe patient population selected for this study consists of patients with advanced-stage melanoma who are receiving Nivolumab and Ipilimumab.\n\nFirst, we aim to assess whether such an intervention is feasible in a large proportion of patients, as many patients experience disease-related and treatment-related side effects.\n\nSecondary objectives are to demonstrate that the exercise intervention positively influences the immune system and that this, in turn, leads to an improved response to therapy, thereby positively affecting patient survival, improving quality of life, and reducing treatment-related side effects.",[552],"Metastatic Melanoma",[554,555,556,557,558],"exercise","Immunotherapy","Melanoma","Nivolumab","Ipilimumab","2026-04-26",{"date":513,"type":41},{"date":562,"type":41},"2025-11-14",{"date":564,"type":22},"2028-12-31",{"name":47,"class":48},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":580,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":49},"100636325","beam-mm----hydroxybutyrate-enhanced-adaptive-immunity-in-multiple-myeloma-100636325","NCT07564219","BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma","BEAM-MM","Inclusion Criteria:\n\n* Multiple Myeloma with indication for CAR-T cell therapy with Ciltacabtagene autoleucel (target antigen: BCMA) or a BCMA-directed bispecific antibody (e.g., Teclistamab, Elranatamab, Linvoseltamab).\n* Age ≥18 years on the day the informed consent is signed.\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy.\n* Known history of infection with Human Immunodeficiency Virus (HIV) or Hepatitis.\n* Significant short-term weight loss (\\>10% within the last 6 weeks).\n* ECOG Performance Status ≥2.\n* Prior immunoeffector cell therapy (CAR-T cell therapy or bispecific antibodies).\n* Active immunosuppression due to another condition (e.g., autoimmune disease, second malignancy).\n* Very high tumor burden with high risk for tumor lysis syndrome, as determined by myeloma-specific markers or markedly elevated LDH (per the treating myeloma team).\n* Women of childbearing potential in whom pregnancy cannot be reliably excluded prior to study entry.",{"count":387,"type":22},[25],"This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of immunotherapy in patients with multiple myeloma, while remaining safe and well-tolerated. Patients will be randomly assigned to one of four intervention groups or a control group. The intervention groups will either follow a ketogenic diet (less than 10% of calories from carbohydrates) or receive oral supplementation with deltaG® Ketone Monoester Performance \\[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate; CAS 1208313-97-6; TdeltaS Global, Inc., Oxford, UK\\], administered orally three times daily at either a low dose (13.5 g per serving, 40.5 g\u002Fday) or a high dose (25 g per serving, 75 g\u002Fday), in accordance with the FDA GRAS-approved dosing range. The control group will receive standard nutritional care. The study includes two parts: Part A enrolls patients receiving bispecific antibody treatment, and Part B enrolls patients receiving CAR-T cell therapy. Both dosing levels are applied in each part.",[577,578,579],"Multiple Myeloma (MM)","CAR T Cells","Bispecific Antibodies",[581,582],"Ketogenic Diet","beta-hydroxybutyrate (BHB)",{"date":513,"type":41},{"date":585,"type":41},"2026-01-30",{"date":564,"type":22},{"name":47,"class":48},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":595,"targetDuration":596,"studyType":61,"phases":4,"briefSummary":597,"conditions":598,"keywords":602,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":49},"100632069","characterisation-of-phenotypes-in-acute-heart-failure-patients-100632069","NCT07508891","Characterisation of phenotYpes in aCute Heart faiLure patiEnts","CYCLE","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure.\n* Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* No written informed consent.",{"count":441,"type":22},"10 Years","An observational cohort study to evaluate the benefit of functional parameters, radiomics and blood biomarkers to predict the outcome of patients with acute heart failure.",[599,600,601],"Acute Heart Failure","Decompensated Heart Failure","Cardiogenic Shock",[603,604,605,74,606,607,608,609],"cardiogenic shock","acute heart failure","heart failure","biobank","cohort study","phenotyping","risk prediction","2026-03-30",{"date":612,"type":41},"2026-04-02",{"date":614,"type":41},"2019-03-01",{"date":452,"type":22},{"name":47,"class":48},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":304,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":635,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":648,"locationsCount":49},"100622551","continuous-vital-sign-monitoring-versus-routine-spot-checks-in-patients-after-non-cardiac-surgery-100622551","NCT07385092","Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery","The Effect of Continuous Monitoring Versus Routine Spot-checks on Altered Vital Signs in Patients Recovering From Non-cardiac Surgery on Normal Wards: the \"COME ON, NOW!\" Trial","COME ON NOW","Inclusion Criteria:\n\nConsenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pregnancy\n* Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA)\n* Atrial fibrillation\n* Patients designated Do Not Resuscitate, or are receiving end-of-life care",{"count":626,"type":22},264,[25],"The \"COME ON, NOW!\" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.",[630,631,632,633,634],"Vital Sign Monitoring","Post Operative Complications","Non-cardiac Surgery","RCT","Anesthesiology",[636,637,638,639,640,153,316,641],"continuous vital signs","vital signs","vital sign monitoring","post-operative care","anesthesiology","post-operative complications","2026-02-27",{"date":644,"type":41},"2026-03-02",{"date":646,"type":41},"2026-02-24",{"date":517,"type":22},{"name":47,"class":48},{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":171,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":658,"conditions":659,"keywords":662,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":49},"100475124","the-global-cardiovascular-risk-consortium-100475124","NCT05466825","The Global Cardiovascular Risk Consortium","Predicting Cardiovascular Risk by Geographical Region and Sex Using Classical Cardiovascular Risk Factors","Inclusion Criteria:\n\nPopulation-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.\n\nExclusion Criteria:\n\n* Participants with age below 18 years\n* No information on the outcome of interest\n* No information on the exposure of interest (CVD risk factors)\n* History of CVD at baseline",{"count":657,"type":22},3000000,"The Global Cardiovascular Risk Consortium (GCVRC) brings together harmonized individual-level data from currently more than 2 million (anticipated: approximately 3 million) individuals across 133 cohorts, 40 countries, and 6 continents, with recruitment ongoing. The GCVRC examines the impact of classical cardiovascular risk factors-such as body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (CVD) and death from any cause worldwide.",[660,661],"All-cause Mortality","Cardiovascular Disease",[661,663,664,665,666,667,668,669,670],"Cardiovascular Risk Factors","Risk Factor Modification","Global","Lifetime Gain","Lifetime estimates","Projected risk reductions","Lifetime difference","Implementation strategies","2026-02-25",{"date":642,"type":41},{"date":674,"type":41},"2019-09-20",{"date":676,"type":22},"2028-06-30",{"name":47,"class":48},{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":684,"targetDuration":686,"studyType":61,"phases":4,"briefSummary":687,"conditions":688,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":690,"startDateStruct":691,"completionDateStruct":692,"leadSponsor":694,"locationsCount":4},"100627034","complications-associated-with-radiofrequency-microneedling-in-dermatology-a-delphi-consensus-100627034","NCT07443384","Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus","Inclusion Criteria:\n\n* Board-certified in dermatology or plastic surgery,\n* At least five years of clinical experience using energy-based devices,\n* Documented experience of at least 5 years and\u002For publications related to RFMN\n\nExclusion Criteria:\n\n* not meeting inclusion critera",{"count":685,"type":22},30,"3 Months","Radiofrequency microneedling (RFMN) combines controlled delivery of radiofrequency energy into the dermis or subcutaneous tissue through arrays of insulated or non-insulated microneedles. This targeted thermal stimulation induces fibroblast (re-)activation leading to collagen remodeling and neocollagenesis, leading to clinical improvement in skin laxity and rhytides. Despite widespread clinical use, recent FDA announcements have highlighted concerns regarding potentially serious complications associated with RFMN treatments. Given this evolving landscape, consensus-based expert guidance is essential to support clinicians in navigating device selection, treatment parameters, patient counselling, and safety protocols. The present Delphi consensus aims to provide structured expert recommendations to address these emerging challenges.",[689],"Radiofrequency Microneedling",{"date":644,"type":41},{"date":482,"type":22},{"date":693,"type":22},"2026-10-01",{"name":47,"class":48},""]